How semaglutide works: the GLP-1 science explained

The incretin system, briefly

After you eat, your gut releases hormones called incretins that tell the pancreas to release insulin. The most important is glucagon-like peptide-1 (GLP-1), which does three things: slows stomach emptying so you feel full longer, acts on appetite centers in the brain to reduce hunger, and boosts glucose-dependent insulin secretion. Natural GLP-1 is broken down within minutes; semaglutide is engineered to resist that breakdown and act for days.

What semaglutide does at the receptor

Semaglutide binds and activates the GLP-1 receptor, amplifying all three effects of the natural hormone. The appetite and gastric-emptying effects are what patients notice most: meals feel satisfying sooner, hunger and food-seeking fall, and total caloric intake drops. Over months, this produces the weight loss quantified in STEP 1 (~14.9%) and sustained in STEP 5 (~15.2% at two years).

Why the same mechanism helps blood sugar and weight

One elegant feature of GLP-1 biology is that a single mechanism addresses two problems at once, which is why semaglutide exists in both a diabetes form (Ozempic) and a weight-management form (Wegovy) at different doses. The glucose-dependent nature of its insulin effect is crucial: semaglutide enhances insulin release only when blood sugar is elevated, and it simultaneously suppresses glucagon. Because the insulin effect switches off as glucose normalizes, semaglutide alone carries a low risk of hypoglycemia — unlike older diabetes drugs. The weight effect and glucose effect share the same receptor activity but express through different tissues: pancreas (insulin/glucagon), gut (emptying), and brain (appetite). This distributed action is why benefits extend to blood pressure, lipids, and inflammation, and ultimately to the cardiovascular event reduction seen in the SELECT trial.

Why it's a once-weekly injection

Natural GLP-1 lasts minutes. Semaglutide is engineered with a fatty-acid chain that binds albumin in the blood, extending its half-life to about a week — long enough for stable once-weekly dosing. That design underpins the slow titration schedule, which governs both efficacy and tolerability, and — on dose-tiered plans — your monthly bill. Understanding the mechanism demystifies the practical rules: the once-weekly schedule follows from the half-life, the slow titration from the gut effects driving nausea, and the weight regain after stopping from the fact that the appetite signal disappears when the drug clears. Nothing about semaglutide's behavior is arbitrary once you see the biology underneath it.

Frequently asked questions

Oral vs injectable: same molecule, different delivery

Semaglutide exists in both injectable and oral forms, and understanding why illuminates the biology. The injectable (Ozempic, Wegovy, and compounded versions) delivers semaglutide under the skin, from which it is absorbed steadily thanks to the albumin-binding design that gives it a week-long half-life. The oral form (Rybelsus) faces a harder problem: peptides like semaglutide are normally destroyed by stomach acid and digestive enzymes, and absorbed poorly across the gut wall. Oral semaglutide solves this with an absorption enhancer that creates a small, temporary window for uptake in the stomach — which is also why it must be taken on an empty stomach with minimal water and a waiting period before eating. The trade-off is bioavailability: only a small fraction of an oral dose reaches the bloodstream, so oral doses are much larger in milligrams than injectable doses to achieve comparable exposure. For weight management specifically, the injectable 2.4 mg dose has the strongest evidence base (the STEP trials), while higher-dose oral formulations for obesity have been studied more recently. In the compounded market, injectable semaglutide dominates because the vial-and-syringe format is straightforward to compound and dose. The mechanism is identical in both cases — GLP-1 receptor agonism reducing appetite and slowing gastric emptying — but the delivery route shapes dosing, timing, and which evidence applies.

Oral vs injectable: same molecule, different delivery

Semaglutide exists in both injectable and oral forms, and understanding why illuminates the biology. The injectable (Ozempic, Wegovy, and compounded versions) delivers semaglutide under the skin, from which it is absorbed steadily thanks to the albumin-binding design that gives it a week-long half-life. The oral form (Rybelsus) faces a harder problem: peptides like semaglutide are normally destroyed by stomach acid and digestive enzymes, and absorbed poorly across the gut wall. Oral semaglutide solves this with an absorption enhancer that creates a small, temporary window for uptake in the stomach — which is also why it must be taken on an empty stomach with minimal water and a waiting period before eating. The trade-off is bioavailability: only a small fraction of an oral dose reaches the bloodstream, so oral doses are much larger in milligrams than injectable doses to achieve comparable exposure. For weight management specifically, the injectable 2.4 mg dose has the strongest evidence base (the STEP trials), while higher-dose oral formulations for obesity have been studied more recently. In the compounded market, injectable semaglutide dominates because the vial-and-syringe format is straightforward to compound and dose. The mechanism is identical in both cases — GLP-1 receptor agonism reducing appetite and slowing gastric emptying — but the delivery route shapes dosing, timing, and which evidence applies.

References

1. Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
2. Novo Nordisk. Wegovy Prescribing Information — clinical pharmacology.
3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes (SELECT). N Engl J Med. 2023.
4. SemaglutideGLPOne science journal, July 2026.

Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.

Keep reading